Thursday, March 31, 2016

Impact of Recent Developments in Lung Cancer on the Practice of Pathology

Philip T. Cagle MDTimothy C. Allen MD, JDEric H. Bernicker MDYimin Ge MDAbida Haque MDRoberto Barrios MD
From the Department of Pathology and Genomic Medicine (Drs Cagle, Ge, Haque, and Barrios)
and Houston Methodist Cancer Center (Dr Bernicker),
Houston Methodist Hospital, Houston, Texas; and the Department of Pathology and Laboratory Medicine, University of Texas Medical Branch, Houston (Dr Allen).

"Even with these caveats, the participation of surgical pathologists and cytopathologists in biomarker testing for lung cancer, while already crucial, becomes even more intimate when the test is directly interpreted by the pathologist using tools of routine practice and is performed in the pathologist-managed histology laboratory. Current requirements of the FDA will likely be modified in the future by pressures from the patients, their oncologists, and their advocates. The potential for impact of biomarker testing with IHC on the practice of pathology is extremely large, given the number of patients receiving a diagnosis of lung cancer."

No comments:

Post a Comment